[THE INVESTOR] SK Chemicals said on June 5 it has received domestic marketing approval for its chickenpox vaccine NBP608.
With the nod from the Ministry of Food and Drug Safety, the chemical and biopharmaceutical arm of SK Group is expected to commercialize NBP608, its forth self-developed vaccine here, following quadrivalent flu vaccine and herpes zoster vaccine.
“We will continue to diversify our revenue and accelerate overseas expansion through the commercialization of the chickenpox vaccine, one of the mandatory prevention vaccines,” said SK Chemicals CEO Park Man-hoon.
The company had conducted phase 3 global clinical studies of NBP608 on 499 young children at 19 sites to prove the drug candidate’s efficacy and safety.
SK Chemicals said it plans to make inroads overseas with the vaccine, especially developing countries which are recently simplifying their regulatory procedures for the medicines approved by the Korean health authorities.
The vaccine business has been SK Chemical’s focused area, pouring some 400 billion won (US$373.58 million) worth investment into a manufacturing plant in Andong, North Gyeongsang Province, and related R&D over the past 10 years. To sharpen its competitiveness, SK Chemical has decided to spin off the vaccine unit on July 1.
By Park Han-na (firstname.lastname@example.org)